References
- Rizzo S, Bronte G, Fanale D, Corsini L, Silvestris N, Santini D, Gulotta G, Bazan V, Gebbia N, Fulfaro F, et al. Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?. Cancer Treat Rev 2010; 36:Suppl 3 S56 - 61; http://dx.doi.org/10.1016/S0305-7372(10)70021-9; PMID: 21129611
- Tomas A, Futter CE, Eden ER. EGF receptor trafficking: consequences for signaling and cancer. Trends Cell Biol 2014; 24:26 - 34; http://dx.doi.org/10.1016/j.tcb.2013.11.002; PMID: 24295852
- Thiel A, Ristimäki A. Toward a Molecular Classification of Colorectal Cancer: The Role of BRAF. Front Oncol 2013; 3:281; http://dx.doi.org/10.3389/fonc.2013.00281; PMID: 24298448
- Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337 - 45; http://dx.doi.org/10.1056/NEJMoa033025; PMID: 15269313
- Osumi H, Matsusaka S, Shinozaki E, Suenaga M, Mingyon M, Saiura A, Ueno M, Mizunuma N, Yamaguchi T. Acquired drug resistance conferred by a KRAS gene mutation following the administration of cetuximab: a case report. BMC Res Notes 2013; 6:508; http://dx.doi.org/10.1186/1756-0500-6-508; PMID: 24304820
- Markman B, Javier Ramos F, Capdevila J, Tabernero J. EGFR and KRAS in colorectal cancer. Adv Clin Chem 2010; 51:71 - 119; http://dx.doi.org/10.1016/S0065-2423(10)51004-7; PMID: 20857619
- Tougeron D, Cortes U, Ferru A, Villalva C, Silvain C, Tourani JM, Levillain P, Karayan-Tapon L. Epidermal growth factor receptor (EGFR) and KRAS mutations during chemotherapy plus anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer. Cancer Chemother Pharmacol 2013; 72:397 - 403; http://dx.doi.org/10.1007/s00280-013-2211-0; PMID: 23765179
- Esposito C, Rachiglio AM, La Porta ML, Sacco A, Roma C, Iannaccone A, Tatangelo F, Forgione L, Pasquale R, Barbaro A, et al. The S492R EGFR ectodomain mutation is never detected in KRAS wild type colorectal carcinoma before exposure to EGFR monoclonal antibodies. Cancer Biol Ther 2013; 14:1143 - 6; http://dx.doi.org/10.4161/cbt.26340; PMID: 24025416